Literature DB >> 25089370

Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors.

Slavka Hamulakova1, Ladislav Janovec, Martina Hrabinova, Katarina Spilovska, Jan Korabecny, Pavol Kristian, Kamil Kuca, Jan Imrich.   

Abstract

A series of novel tacrine derivatives and tacrine-coumarin heterodimers were designed, synthesized, and biologically evaluated for their potential inhibitory effect on both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Of these compounds, tacrine-coumarin heterodimer 7c and tacrine derivative 6b were found to be the most potent inhibitors of human AChE (hAChE), demonstrating IC50 values of 0.0154 and 0.0263 μM. Ligands 6b, 6c, and 7c exhibited the highest levels of inhibitory activity against human BuChE (hBuChE), demonstrating IC50 values that range from 0.228 to 0.328 μM. Docking studies were performed in order to predict the binding modes of compounds 6b and 7c with hAChE/hBuChE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25089370     DOI: 10.1021/jm5008648

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  23rd Interdisciplinary Toxicological Conference TOXCON 2018.

Authors: 
Journal:  Interdiscip Toxicol       Date:  2018-08-06

2.  Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease.

Authors:  An Zhou; Jianping Hu; Lirong Wang; Guochen Zhong; Jian Pan; Zeyu Wu; Ailing Hui
Journal:  J Mol Model       Date:  2015-10-05       Impact factor: 1.810

3.  In silico study of tacrine and acetylcholine binding profile with human acetylcholinesterase: docking and electronic structure.

Authors:  Letícia A Nascimento; Érica C M Nascimento; João B L Martins
Journal:  J Mol Model       Date:  2022-08-10       Impact factor: 2.172

Review 4.  An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.

Authors:  João Paulo B Lopes; Luana Silva; Diogo S Lüdtke
Journal:  RSC Med Chem       Date:  2021-09-08

5.  Synthesis and molecular modeling studies of cholinesterase inhibitor dispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrolidines].

Authors:  M Adel Youssef; Siva S Panda; Riham A El-Shiekh; ElSayed M Shalaby; Dalia R Aboshouk; Walid Fayad; Nehmedo G Fawzy; Adel S Girgis
Journal:  RSC Adv       Date:  2020-06-08       Impact factor: 4.036

6.  Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.

Authors:  Tao Su; Tianhua Zhang; Shishun Xie; Jun Yan; Yinuo Wu; Xingshu Li; Ling Huang; Hai-Bin Luo
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

7.  Exploring Biological Activity of 4-Oxo-4H-furo[2,3-h]chromene Derivatives as Potential Multi-Target-Directed Ligands Inhibiting Cholinesterases, β-Secretase, Cyclooxygenase-2, and Lipoxygenase-5/15.

Authors:  Malose J Mphahlele; Emmanuel N Agbo; Samantha Gildenhuys; Itumeleng B Setshedi
Journal:  Biomolecules       Date:  2019-11-13

8.  Facile preparation of fluorescent water-soluble non-conjugated polymer dots and fabricating an acetylcholinesterase biosensor.

Authors:  Cai-Hong Li; Wei-Feng Wang; Nsanzamahoro Stanislas; Jun-Li Yang
Journal:  RSC Adv       Date:  2022-03-10       Impact factor: 3.361

Review 9.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.

Authors:  Angela Stefanachi; Francesco Leonetti; Leonardo Pisani; Marco Catto; Angelo Carotti
Journal:  Molecules       Date:  2018-01-27       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.